How to sell your startup equity: a practical guide for employees and shareholders

You joined early. You believed in the mission. You took a lower salary in exchange for equity that might, someday, be worth something real. Now it is—at least on paper.

The problem? "On paper" doesn't pay a mortgage. It doesn't fund your kid's school. It doesn't diversify a portfolio that's dangerously concentrated in a single private company. And yet, for most startup employees and early shareholders, turning that equity into actual money remains one of the least understood parts of working in tech.

The good news: the secondary market for private company stock has never been more active. Deal volume hit a record $226 billion in 2025, according to Evercore. More platforms, more buyers, and more structured transaction options exist today than at any point in the market's history.

The less-good news: selling startup equity is still complex. Legal restrictions, tax consequences, company approval processes, and pricing uncertainty all play a role. Getting it wrong can cost you real money—or block the transaction entirely.

This guide walks through the entire process: what you need to know before you sell, how secondary sales actually work, the mistakes to avoid, and how to prepare for a successful transaction.

Understanding Your Equity Before Trying to Sell

Before you can sell anything, you need to know exactly what you own. That sounds obvious, but the details matter enormously—and most employees don't have a clear picture of what's sitting in their equity compensation package.

Know Your Equity Type

Not all startup equity is created equal. The type of equity you hold determines your rights, your tax treatment, and your ability to sell.

Common stock vs. preferred stock. Most employees hold common stock or options that convert into common stock upon exercise. Early investors and venture capital firms typically hold preferred stock, which comes with additional rights—like liquidation preferences, anti-dilution protections, and sometimes special voting provisions. Common stock generally trades at a discount to preferred in secondary transactions, reflecting the difference in economic rights. Understanding which class of stock you hold (and what rights attach to it) is essential before pricing any sale.

Stock options: ISOs and NSOs. If you received stock options, the first question is whether they're incentive stock options (ISOs) or non-qualified stock options (NSOs). Both give you the right to purchase company stock at a fixed price (the "strike price"), but the tax treatment is very different—particularly when you exercise and later sell. We'll cover the tax implications in detail below.

RSUs (restricted stock units). RSUs represent a promise to deliver shares after vesting conditions are met. Once vested, RSUs convert into actual shares of stock. Unlike options, there's no exercise price to pay—but you will owe income tax on the value of the shares at the time they vest. At a private company, this creates a particular challenge: you may owe taxes on shares you can't easily sell to generate the cash to pay that tax bill.

Exercised shares. If you've already exercised your options, you hold actual shares. This is typically the most straightforward position to sell on the secondary market, since the shares are already issued in your name.

Check Your Vesting and Exercise Status

Vesting determines when your equity actually belongs to you. Most startup equity awards vest over four years with a one-year cliff—meaning you earn nothing during the first year, then receive 25% of your total grant, with the remainder vesting monthly or quarterly over the following three years.

Before exploring a sale, confirm two things. First, how much of your equity is fully vested? Only vested equity can be sold or exercised. Second, if you hold options, have you exercised them? Unexercised options are not shares—they're the right to purchase shares at the strike price. Some secondary buyers will work with sellers who hold unexercised options, but the process is more complex and may require exercising as part of the transaction.

If you've left the company, pay close attention to your post-termination exercise window. Most option agreements give departing employees 90 days to exercise their vested options after leaving. Miss that window and your options could expire worthless—regardless of how much the company is worth.

Understand Your Shareholder Rights

Every equity grant comes with governing documents—an option agreement, a stock purchase agreement, or an RSU award notice—that define what you can and can't do with your shares. These documents, along with the company's bylaws and any shareholder agreements, spell out your transfer rights.

Key questions to answer: Do you have the right to transfer your shares to a third party? Are there restrictions on who can buy them? Is there a right of first refusal (ROFR) that gives the company or existing investors the first opportunity to purchase your shares at the proposed sale price? Are there lock-up provisions that prevent sales during certain periods?

These aren't theoretical concerns. They directly determine whether you can sell, to whom, and on what timeline.

Can You Legally Sell Your Shares? Key Factors to Check

This is where many sellers get tripped up. Wanting to sell and being able to sell are two different things in private markets.

Company Approval and Transfer Restrictions

Most private companies require board or company approval before any shares can be transferred to a new owner. This isn't unusual or adversarial—it's a standard feature of private company governance, designed to give the company visibility into (and control over) its cap table.

In practice, this means you generally can't just find a buyer and close a deal on your own. The company needs to sign off, and the process for obtaining that approval varies widely. Some companies have established secondary sale programs with clear procedures. Others handle requests ad hoc, and timelines can stretch.

Start by reviewing your option plan or shareholder agreement for the specific transfer approval language. Then, talk to your company's HR or legal team to understand the current process. The sooner you know what's required, the fewer surprises you'll encounter later.

Right of First Refusal (ROFR) and Other Constraints

A right of first refusal gives the company—and in some cases, existing investors—the right to match any third-party purchase offer before the sale can proceed. ROFRs are embedded in the shareholder agreements of most venture-backed companies.

Here's how it typically works: you agree on terms with a buyer, then notify the company of the proposed transaction. The company (or designated ROFR holders) then have a set period—usually 30 to 60 days—to decide whether to exercise their right and purchase the shares on the same terms. If they exercise, the shares go to them instead of your intended buyer. If they waive or let the period expire, the sale proceeds as planned.

ROFRs can affect both timing and certainty. A buyer who knows the deal may be intercepted by the company may offer less favorable terms to account for that risk. And the ROFR clock adds weeks to the transaction timeline, which matters if you're working against a personal deadline.

Some companies also maintain a right of first offer (ROFO), which requires you to offer shares to the company before soliciting outside buyers. The distinction matters: a ROFR is reactive (the company responds to a deal you've already negotiated), while a ROFO is proactive (you must approach the company first).

Secondary Sale Policies

Company policies on secondary sales vary dramatically. Some late-stage companies—SpaceX, Stripe, and others—have run regular tender offers or company-approved secondary programs that give employees structured access to liquidity. Others may restrict or delay secondary transactions, particularly if an IPO or fundraise is approaching.

A growing number of companies have recognized that employee liquidity is a retention tool, not a threat. According to research from Ledgy, secondary transactions are most commonly driven by companies themselves, often as part of funding rounds where existing shareholders are given the opportunity to sell alongside new investment.

If your company hasn't historically allowed secondary sales, that doesn't necessarily mean they won't. Market norms are evolving, and many companies are becoming more accommodating as employees (and their advisors) push for clearer liquidity pathways. The worst thing you can do is assume the answer is no without asking.

Common Reasons Employees and Early Shareholders Want to Sell

People sell startup equity for all kinds of reasons, and none of them require apologizing. Understanding your own motivation helps you make better decisions about timing, sizing, and structuring a sale.

Access to Liquidity Before an IPO or Acquisition

This is the most common driver. Life doesn't pause while you wait for an exit event that may be years away—or may never come. A down payment on a home, a child's education, a career transition, or simply the desire to have cash in the bank after years of deferred compensation are all legitimate reasons to explore liquidity.

The key insight: you don't have to sell everything. A partial sale—converting 20% or 30% of your holdings into cash while retaining the rest—can address immediate needs without fully exiting your position.

Tax Planning and Deadline-Driven Decisions

For holders of incentive stock options, tax timing can be a powerful motivator. When you exercise ISOs and hold the shares past the end of the calendar year, the spread between your strike price and the fair market value at exercise is included as income in your alternative minimum tax (AMT) calculation. According to tax guidance from Carta, this can create a significant tax liability—sometimes hundreds of thousands of dollars—even though you haven't sold a single share.

Under the One Big Beautiful Bill Act (OBBBA), signed into law on July 4, 2025, AMT exemption amounts have been made permanent at higher levels. For 2026, the AMT exemption is $90,100 for single filers and $140,200 for married couples filing jointly. However, the same law accelerated the phase-out of those exemptions, with thresholds dropping to $500,000 (single) and $1,000,000 (joint) and the phase-out rate doubling from 25% to 50%. The net effect: more high-income earners with large ISO exercises may find themselves in AMT territory.

Some employees time secondary sales to coincide with or follow ISO exercises, using sale proceeds to fund their tax liability. Others sell to avoid the exercise-and-hold risk entirely. In either case, the tax calendar can drive urgency that has nothing to do with the company's fundamentals.

If you hold ISOs, working with a tax advisor before exercising or selling isn't optional—it's essential. The interplay between exercise timing, holding periods, AMT exposure, and capital gains treatment is complex enough that even sophisticated employees routinely get it wrong.

Rebalancing Your Personal Investment Portfolio

Concentration risk is real. If 60%, 70%, or 80% of your net worth is tied up in a single private company's stock, your financial future is disproportionately dependent on one outcome. That might be the right bet—but it should be a conscious one.

Selling a portion of your startup equity to diversify into other investments—public equities, real estate, fixed income, or other alternatives—is a standard wealth management practice. Financial advisors consistently recommend reducing single-stock concentration, and startup equity is one of the most concentrated, highest-risk positions an individual can hold.

The goal isn't to eliminate exposure to your company's upside. It's to right-size that exposure relative to your overall financial picture.

How Secondary Share Sales Work

If you've decided to explore selling, here's what the process actually looks like.

Direct vs. Platform-Based Transactions

There are two primary paths to selling private company shares.

Direct transactions involve finding an individual or institutional buyer on your own (or through a broker), negotiating terms, and completing the paperwork. This approach offers flexibility but requires significant effort: identifying qualified buyers, determining fair pricing, drafting legal documentation, and managing the company approval process yourself.

Platform-based transactions route the sale through a regulated secondary marketplace—like Augment—that matches sellers with vetted buyers, facilitates pricing, handles documentation, and manages compliance workflows including ROFR processing. Platforms typically charge a commission or transaction fee in exchange for streamlining the process and providing access to a broader buyer network.

For most individual sellers, platform-based transactions are more practical. They reduce the administrative burden, provide pricing guidance based on market activity, and bring structure to a process that can otherwise be opaque and slow.

Pricing, Documentation, and Timing

Pricing private company shares is more art than science. There's no public market price to reference, so pricing typically draws on several inputs: the company's most recent 409A valuation (the independent appraisal used to set fair market value for tax purposes), the last funding round valuation, comparable company trading data, and real-time buyer demand.

Secondary shares often trade at a discount to the company's last preferred-stock funding round. This reflects the difference in rights between common and preferred stock, the illiquidity of the asset, and the uncertainty inherent in any private company investment. Discounts can range widely—from single digits for the most in-demand names to 30% or more for less liquid companies.

Documentation typically includes a stock purchase agreement, representations and warranties from both parties, and any required company consent forms. If the transaction involves an SPV structure, there will be additional subscription documents.

Timing is rarely fast. Between initiating a sale, securing company approval, processing any ROFR period, and completing legal documentation, transactions commonly take four to eight weeks. In some cases, the process can extend longer—particularly if the company is slow to respond or if a ROFR is exercised.

Who's Buying Startup Equity?

The buyer universe for private company shares has expanded significantly. Today's secondary market participants include institutional secondaries funds that specialize in acquiring private company stakes, family offices seeking pre-IPO exposure, accredited individual investors looking to build private market portfolios, and SPVs (special purpose vehicles) that pool capital from multiple investors to acquire shares in a single company.

SPVs have become particularly important infrastructure in the secondary market. By aggregating multiple investors into a single entity, SPVs simplify cap table management for the company (which sees one line item instead of dozens of individual shareholders) while giving smaller investors access to deals that might otherwise require minimums they can't meet individually.

The diversity of buyers is generally good news for sellers: more competition among buyers tends to support better pricing and faster execution.

Key Steps to Prepare for a Successful Equity Sale

Preparation is where most of the value is created (or lost) in a secondary transaction. The better prepared you are before engaging with buyers or platforms, the smoother the process will be.

Talk to the Company or HR First

This is step one, and it's non-negotiable. Before listing your shares on any platform or engaging with potential buyers, reach out to your company's HR, legal, or equity administration team to understand the current landscape.

Ask specifically about the company's secondary sale policy, any upcoming liquidity events (tender offers, structured secondary programs), the ROFR process and typical timeline, any blackout periods that might affect timing, and whether there are preferred platforms or channels the company works with.

Some companies may surprise you with more flexibility than you expected. Others may point you toward a structured program that's easier and more favorable than an independent sale. Either way, starting with the company gives you the clearest picture of what's possible.

Gather Your Documentation

A secondary sale requires documentation. Having these materials organized before you start saves time and signals to buyers (and platforms) that you're a serious, prepared seller.

Essential documents include your original option agreement or RSU award notice (confirming the grant date, number of shares, vesting schedule, and exercise price), your shareholder agreement or equity plan (detailing transfer restrictions, ROFR provisions, and approval requirements), evidence of exercise (if applicable—your exercise notice and payment confirmation), the company's most recent 409A valuation (which establishes fair market value for tax purposes), and any cap table information you have access to (share class, total shares outstanding, conversion ratios).

If you're unsure what you have, your company's equity administration team or the cap table management platform they use (often Carta, Pulley, or AngelList) can typically provide copies of your core documents.

Know Your Tax Position

Tax consequences are the most commonly underestimated aspect of selling startup equity. The amount you owe—and when you owe it—depends on the type of equity you hold, how long you've held it, and how the sale is structured.

For ISO holders, the distinction between a qualifying and disqualifying disposition is critical. A qualifying disposition—one that occurs at least two years after the option grant date and at least one year after the exercise date—allows the gain to be taxed at long-term capital gains rates rather than ordinary income rates. Missing either of those thresholds converts the sale into a disqualifying disposition, which can significantly increase your tax bill.

For anyone holding shares in a C-corporation acquired before the company crossed $50 million in gross assets, qualified small business stock (QSBS) exclusions may apply. Under Section 1202 of the Internal Revenue Code, eligible shares held for at least five years may qualify for exclusion of up to $10 million (or $15 million for stock acquired after July 4, 2025) in capital gains from federal taxes. This is a substantial potential benefit—but the eligibility requirements are specific and must be tracked carefully.

The bottom line: talk to a tax advisor before you sell, not after. The cost of professional tax guidance is almost always a fraction of the savings it generates.

Common Mistakes to Avoid When Selling Startup Equity

Selling Without Understanding Restrictions

The single most common mistake is attempting to sell shares without fully understanding the transfer restrictions that apply. This can result in a deal that gets blocked by the company, delays that cause the buyer to walk away, or—in worst-case scenarios—a transaction that the company refuses to recognize on its books.

Review your governing documents thoroughly. If anything is unclear, ask your company or consult a securities attorney. A small investment in legal clarity upfront can prevent a much larger problem down the road.

Underestimating Tax Consequences

Tax surprises are the second most common pitfall. Common scenarios include exercising ISOs late in the year and discovering a six-figure AMT liability with no cash to pay it, selling shares in a disqualifying disposition and paying ordinary income tax rates instead of the expected capital gains rate, or failing to account for state taxes (particularly relevant in high-tax states like California, which taxes capital gains as ordinary income).

Run the numbers before committing to a sale. Model different scenarios—including the possibility that the sale price or timing changes—and understand the tax impact of each.

Not Shopping Around for the Best Deal

Private company shares don't have a single "market price." Pricing varies across platforms, buyers, and transaction structures. The first offer you receive may not be the best offer available.

Compare terms from multiple sources. Look beyond the headline price to understand the full transaction economics: commissions, fees, ROFR risk, and timeline. A nominally higher offer that comes with more uncertainty or higher fees may not actually put more money in your pocket.

Some platforms offer price discovery tools or indicative pricing that can help you benchmark offers. Use them. In a market without centralized price transparency, informed sellers consistently achieve better outcomes than those who accept the first bid.

How Augment Helps Employees and Shareholders Sell Startup Equity With Confidence

Augment is a private stock marketplace built to make secondary transactions simpler, more transparent, and more accessible for employees, founders, and long-term shareholders.

The platform supports compliant, structured secondary transactions through SPV-based deals that reduce friction for both sellers and buyers. Built-in tools handle ROFR processing, disclosure requirements, and legal documentation—so sellers don't have to navigate those workflows alone.

Augment provides transparent pricing informed by real secondary market activity and connects sellers with a vetted network of accredited and institutional investors actively seeking exposure to top pre-IPO companies. Whether you're looking to sell a portion of your holdings for diversification or seeking a full exit from a position, the platform is designed to support both partial and complete liquidity.

For employees at late-stage private companies, the question isn't whether secondary liquidity is possible. It's whether you're working with a pre-IPO investment platform that makes the process clear, compliant, and fair.

Final Takeaways for Selling Your Startup Equity in 2026

Selling startup equity isn't as simple as clicking a button—but it's far more accessible than it was even a few years ago. The secondary market is larger, more liquid, and more structured than at any point in its history. Individual employees and shareholders have more options than ever.

Here's what matters most:

Know what you own. Understand the type of equity you hold, your vesting and exercise status, and the specific rights and restrictions that apply to your shares. The details matter.

Understand your company's policies. Don't assume you can't sell—and don't assume you can. Talk to HR or legal early in the process to understand the current rules, timelines, and any upcoming liquidity events.

Prepare early. Equity sales take time. Gathering documentation, understanding tax implications, securing company approval, and finding the right buyer or platform are all steps that benefit from advance planning. Rushing into a sale because you suddenly need liquidity is a recipe for suboptimal outcomes.

Get professional advice. A tax advisor can help you model different exercise and sale scenarios to minimize your liability. A securities attorney can review your governing documents and flag any issues. The cost is almost always justified.

Compare your options. The secondary market has multiple platforms, buyers, and transaction structures. Shop around. The right channel for your specific situation depends on your company, your share class, your timeline, and the amount you're looking to sell.

Secondary platforms like Augment are making equity sales easier, safer, and more accessible across private markets. But the market still rewards prepared sellers. The more you know going in, the better your outcome.

FAQs

Can I sell my startup equity before an IPO?

Yes—sometimes. Private-company equity can be sold before an IPO or acquisition, but only if your company’s governing documents and current policies allow transfers and the company approves the transaction. Many employees get liquidity through company-led tender offers or company-approved secondary programs, which tend to be more straightforward than trying to sell independently.

How do I know if I’m allowed to sell my startup shares?

Check three things: (1) what you actually hold (options, RSUs, or shares), (2) what restrictions apply (company approval, ROFR/ROFO, lockups, blackout periods), and (3) whether your company has an approved process or window for secondary sales. Even if you find a buyer, the company can still delay or block a transfer if the required steps aren’t followed.

What taxes apply when selling startup equity?

It depends on the equity type and timing. ISOs and NSOs can be taxed very differently, and exercising ISOs can create AMT exposure. RSUs are typically taxed as ordinary income when they vest. If you’re selling shares, gains are often capital gains, but holding periods and your cost basis matter. The smart move is to model scenarios with a tax advisor before you sign anything—structure and timing can materially change what you owe.

Who buys private startup shares in secondary transactions?

Common buyers include institutional secondaries funds, family offices, and accredited individual investors looking for pre-IPO exposure. Many transactions also use SPVs (special purpose vehicles), which pool capital from multiple investors into a single entity—simplifying the company’s cap table while allowing smaller checks to participate.

Augment Markets, Inc. is a technology company offering software and data services with securities-related services offered through its wholly-owned but separately managed subsidiary Augment Capital, LLC, Member of FINRA/ SIPC.

‍

Important Disclosures: This material has been prepared for informational purposes only. None of the information provided represents an offer or the solicitation of an offer to buy or sell any security. The information provided does not constitute investment, legal, tax, or accounting advice. You should consult with qualified professionals before making any investment decisions. Investing in private securities involves substantial risk, including the potential loss of principal. Private securities are typically illiquid, have limited pricing transparency, and often require longer holding periods. These investments are available exclusively to qualified accredited investors and offer no guarantee of returns. Additionally, past performance of private securities does not indicate or predict future results.

‍